Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 179-183

  De Faria, Ana Paula Cabral ^a   Fontana, Vanessa ^a   Modolo, Rodrigo ^a   Barbaro, Natália Ruggeri ^a   Sabbatini, Andréa Rodrigues ^a   Pansani, Isabella Fagian ^a   Ferreira Melo, Silvia E ^a   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Arterial stiffness; Flow mediated dilation; Oxidative stress; Refractory hypertension

Indexed keywords

8 ISOPROSTANE; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SPIRONOLACTONE; TRIACYLGLYCEROL; UREA DERIVATIVE; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIHYPERTENSIVE AGENT; PROSTAGLANDIN F2 ALPHA;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL FUNCTION; CARDIOVASCULAR SYSTEM EXAMINATION; CONTROLLED STUDY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW MEDIATED DILATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PULSE WAVE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; DRUG RESISTANCE; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; DINOPROST; DRUG RESISTANCE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; VASCULAR STIFFNESS;

EID: 84897446371     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.009     Document Type: Article

References (45)

1. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
2. DiBona G.F. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension 2000, 36:1083-1088.
3. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
4. Figueiredo V.N., Yugar-Toledo J.C., Martins L.C., Martins L.B., de Faria A.P., de Haro Moraes C., et al. Vascular stiffness and endothelial dysfunction: correlations at different levels of blood pressure. Blood Press 2012, 21:31-38.
5. Sutton-Tyrrell K., Newman A., Simonsick E.M., Havlik R., Pahor M., Lakatta E., et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001, 38:429-433.
6. Perticone F., Ceravolo R., Pujia A., Ventura G., Iacopino S., Scozzafava A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104:191-196.
7. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
8. Crimi E., Ignarro L.J., Napoli C. Microcirculation and oxidative stress. Free Radic Res 2007, 41:1364-1375.
9. Beswick R.A., Dorrance A.M., Leite R., Webb R.C. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001, 38:1107-1111.
10. Zicha J., Dobesova Z., Kunes J. Relative deficiency of nitric oxide-dependent vasodilation in salt-hypertensive Dahl rats: the possible role of superoxide anions. J Hypertens 2001, 19:247-254.
11. Uddin M., Yang H., Shi M., Polley-Mandal M., Guo Z. Elevation of oxidative stress in the aorta of genetically hypertensive mice. Mech Ageing Dev 2003, 124:811-817.
12. Cracowski J.L., Durand T., Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002, 23:360-366.
13. Vazzana N., Ganci A., Cefalu A.B.., Lattanzio S., Noto D., Santoro N., et al. Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. J Am Heart Assoc 2013, 2:e000063.
14. Costa A.P., de Paula R.C., Carvalho G.F., Araujo J.P., Andrade J.M., de Almeida O.L., et al. High sodium intake adversely affects oxidative-inflammatory response, cardiac remodelling and mortality after myocardial infarction. Atherosclerosis 2012, 222:284-291.
15. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:510-526.
16. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J 2013, 34:2159-2219.
17. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
18. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
19. Laurent S., Cockcroft J., Van Bortel L., Boutouyrie P., Giannattasio C., Hayoz D., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
20. Martins L.C., Figueiredo V.N., Quinaglia T., Boer-Martins L., Yugar-Toledo J.C., Martin J.F., et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 2011, 25:532-538.
21. Quinaglia T., Martins L.C., Figueiredo V.N., Santos R.C., Yugar-Toledo J.C., Martin J.F., et al. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens 2011, 25:656-664.
22. Miyajima K., Minatoguchi S., Ito Y., Hukunishi M., Matsuno Y., Kakami M., et al. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res 2007, 30:307-313.
23. Dikalov S.I., Nazarewicz R.R., Bikineyeva A., Hilenski L., Lassegue B., Griendling K., et al. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal 2014, 20:281-294.
24. Hozawa A., Ebihara S., Ohmori K., Kuriyama S., Ugajin T., Koizumi Y., et al. Increased plasma 8-isoprostane levels in hypertensive subjects: the Tsurugaya Project. Hypertens Res 2004, 27:557-561.
25. Rodrigo R., Prat H., Passalacqua W., Araya J., Guichard C., Bachler J.P. Relationship between oxidative stress and essential hypertension. Hypertens Res 2007, 30:1159-1167.
26. Castro M.M., Rizzi E., Ceron C.S., Guimaraes D.A., Rodrigues G.J., Bendhack L.M., et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 2012, 26:162-168.
27. Martinez M.L., Rizzi E., Castro M.M., Fernandes K., Bendhack L.M., Gerlach R.F., et al. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 2008, 599:110-116.
28. Birben E., Sahiner U.M., Sackesen C., Erzurum S., Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J 2012, 5:9-19.
29. Banday A.A., Lokhandwala M.F. Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling. Hypertension 2008, 52:1099-1105.
30. Pierdomenico S.D., Lapenna D., Bucci A., Di Tommaso R., Di Mascio R., Manente B.M., et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005, 18:1422-1428.
31. Flammer A.J., Hermann F., Wiesli P., Schwegler B., Chenevard R., Hurlimann D., et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007, 25:785-791.
32. Serg M., Kampus P., Kals J., Zagura M., Zilmer M., Zilmer K., et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest 2012, 72:427-432.
33. Sica D.A. Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?. Curr Hypertens Rep 2008, 10:415-420.
34. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
35. Dattilo J.B., Makhoul R.G. The role of nitric oxide in vascular biology and pathobiology. Ann Vasc Surg 1997, 11:307-314.
36. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989, 2:997-1000.
37. Dusting G.J., Akita K., Hickey H., Smith M., Gurevich V. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. Br J Pharmacol 1999, 128:337-344.
38. Maron B.A., Michel T. Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase. Circ J 2012, 76:2497-2512.
39. John S., Schmieder R.E. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep 2003, 5:199-207.
40. Wykretowicz A., Guzik P., Kasinowski R., Krauze T., Bartkowiak G., Dziarmaga M., et al. Augmentation index, pulse pressure amplification and superoxide anion production in patients with coronary artery disease. Int J Cardiol 2005, 99:289-294.
41. Kals J., Kampus P., Kals M., Zilmer K., Kullisaar T., Teesalu R., et al. Impact of oxidative stress on arterial elasticity in patients with atherosclerosis. Am J Hypertens 2006, 19:902-908.
42. Thomas S.R., Witting P.K., Drummond G.R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008, 10:1713-1765.
43. Chaudhary K., Buddineni J.P., Nistala R., Whaley-Connell A. Resistant hypertension in the high-risk metabolic patient. Curr Diab Rep 2011, 11:41-46.
44. Lastra G., Whaley-Connell A., Manrique C., Habibi J., Gutweiler A.A., Appesh L., et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008, 295:E110-E116.
45. Callera G.E., Touyz R.M., Tostes R.C., Yogi A., He Y., Malkinson S., et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005, 45:773-779.